^
Association details:
| Biomarker: | IDH1 R132H |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | dasatinib (c-KIT inhibitor, Bcr-abl tyrosine kinase inhibitor, Src kinase inhibitor, EphA2 receptor antagonist, PDGFR β antagonist) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
IDH MUTATIONS DRIVE LEUKEMOGENESIS BY ONCOGENIC ACTIVATION DUE TO INSULATOR DYSFUNCTION
Published date:
05/12/2021
Excerpt:
...IDH1-mut KG1a cells showed higher sensitivity towards the tyrosine kinase inhibitor Dasatinib in a WST-based drug screen, supporting Dasatinib as novel candidate for treatment of AML patients with IDH1 mutation.
